The tumor microenvironment (TME) is a barrier to adoptive cell therapy because it promotes tumor growth and metastasis while suppressing anticancer immune responses. A novel therapy deploys adenoviruses that disrupt and manipulate the TME to create a more immunostimulatory setting. However, delivering the therapy to solid tumors is challenging, as innate or adaptive immune responses often eliminate viruses before they reach the tumor site.
Download this research summary from IsoPlexis to find out how researchers delivered anticancer adenoviruses to tumor sites with the help of a mesenchymal stromal cell-based vector.
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.